MacroGenics Inc (MacroGenics) is engaged in the development and marketing og antibody-based therapeutics for autoimmune disorders, cancer and various infectious diseases. The company operates through one reportable segment, which includes developing and commercializing monoclonal antibody-based therapeutics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

MacroGenics focuseson developing antibody-based therapeutic products to treat cancer made it invest huge amounts in its R&D activities. The company’s pipeline products include enoblituzumab, which is a monoclonal antibody against B7-H3. The company is evaluating enoblituzumab in Phase II for the treatment of patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN). The other pipeline products include: MGC018 (B7-H3) for mCRPC, TNBC, NSCLC, SCCHN, melanoma and solid tumors; Lorigerlimab (PD-1 × CTLA-4) for MSS CRC, NSCLC, mCRPC, Melanoma; Tebotelimab (PD-1 × LAG-3) for solid tumors and heme malignancies; IMGC936 (ADAM9) for NSCLC, gastric, pancreatic, TNBC and other solid tumors; and MGD024 (CD123 × CD3) for Heme malignancies. In FY2022, the company spent US$207.0 million on its R&D activities.